A Study of ASP1951 in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the tolerability and safety profile of
ASP1951 when administered as a single agent and in combination with pembrolizumab in
participants with locally advanced (unresectable) or metastatic solid tumors; characterize
the pharmacokinetic profile of ASP1951 when administered as a single agent and in combination
with pembrolizumab; and determine the recommended phase 2 dose (RP2D) of ASP1951 and/or
maximum tolerated dose (MTD) when administered as a single agent and in combination with
pembrolizumab. This study will also evaluate the anti-tumor effect of ASP1951 when
administered as a single agent and in combination with pembrolizumab.